Catalyst Dossier · compiled by CeliA 🧫

Madrigal Pharmaceuticals, Inc. (MDGL)

Pharmaceutical Preparations · market cap $11.7B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Madrigal Pharmaceuticals (MDGL) is a ~$11.8B market-cap commercial-stage pharma with one approved product, Resmetirom (branded Rezdiffra), for NASH/MASH. The company generated $958M in 2025 revenue but remains unprofitable (-$288M net loss), and faces a critical cash position with only ~4.1 months of runway and $143.3M in net debt. Key upcoming readouts in late 2026 and early 2027 will determine whether Resmetirom's label can expand and whether the HeFH pipeline asset (MGL-3196) progresses.

The catalyst path

2026-08-04Earningsimp 5/10
2026-12-15 (est.)Phase 2 · Resmetiromimp 7/10
2026-12-15 (est.)Phase 3 · Resmetiromimp 9/10
2027-03-15 (est.)Phase 3 · Resmetiromimp 9/10

Pipeline

Asset	Phase	Indication
Resmetirom	Phase 3	NASH
MGL-3196	Phase 3	Heterozygous Familial Hypercholesterolemia

Price & technical context

3-month

-0.3%

6-month

-9.5%

12-month

+76.7%

52-wk range

$287.52–$602.83

vs 50-day MA

+3.8%

vs 200-day MA

+6.1%

Realized vol

68.5%

Max drawdown

-30.9%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MDGL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.